RTTNews BiotechDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 21:04:02·⟳ 抓取 21:15:15 +11m13s·⚡ 决策 10-15 21:17:09 +1m54s·11.9 天前
Adlai Nortye 与礼来、默克(德国)达成 AN4035 联合西妥昔单抗 I 期临床供药合作
这是一份无现金、无里程碑、无股权的 I 期临床供药协议，只带来轻度科学/大药企背书，不改变 ANL 的收入、现金或近期数据读出；盘前已上涨约 4.5% 但成交极薄，且股票近 5 日下跌 22.6% 处于明确下行通道，做多无 edge、做空又无强空催化，风险回报不足。
📄 原文RTTNews Biotech↗ 原文
Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors
Adlai Nortye Group (ANL) has entered into clinical trial collaboration and supply agreements with Eli Lilly and Company…
不做 Adlai Nortye Group（ANL.US）
无现金条款的 I 期免费供药协议，仅轻度背书、无近期业绩增量；盘前已+4.5%且成交极薄，近5日-22.6%处下行通道、下跌原因不明，做多无 edge；亦无强空催化可做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Adlai 与礼来、Merck KGaA 的合作仅是对方免费供药、Adlai 自办 I 期，无任何经济条款，属轻度背书；盘前+4.5%已部分定价，叠加高波动微盘与下行趋势，不构成可交易机会。
消息传播链
- 公司官方新闻稿首发，确认为临床试验协作与免费供药协议，无经济条款。
- RTTNews 转述公司稿，信号即来自此；其称盘前 11.25 美元、+3.4%。市场反应:实时行情显示盘前最高13.31后回落至约11.37（+4.5%），成交仅约2400股。
关键理由
- 大药企愿意供药联合用药提供轻度科学验证，但协议无首付款、里程碑、分成或股权投资。
- 标的仍处 I 期、无可量化患者×定价×渗透率收入弹性，最早商业化兑现遥远。
主要风险
- 微盘临床期生物股日内波动大（20日波动率约5.8%、52周区间0.88–17.25美元），消息面易引发剧烈双向波动。
- 近5日-22.6%的下跌原因不明，若存在未披露利空，盘前反弹可能仅为技术反抽。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 weakens
近5日股价下跌22.6%、10月13日单日-17.3%，未检索到对应的公开利空；下跌原因不明本身构成追多风险，盘前反弹成交极薄。
检索:Adlai Nortye ANL stock October 2026 decline AN4035 news 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失叠加事件无经济条款，支持以风险回报不足回避，而非试探做多。
方向:无可对照先例；免费供药型 I 期协作通常仅有轻度、短暂的情绪反应。
涨幅量级:无同市场、同相位、锚干净的先例可用于校准 tp/sl，故不定交易幅度。
形态:不足以判断见光死模式；当前盘前冲高（高13.31）后回落提示追高风险。
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`adlai nortye an4035 eli lilly merck kgaa cetuximab collaboration | anl an4035 ceacam5 pan-ras adc phase i supply agreement`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - web_search 成功 doubao_search · 1,764 ms
豆包搜索结果（原始查询:Adlai Nortye AN4035 Lilly Merck KGaA cetuximab collaboration supply agreement；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,048 ms
{ - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 2,001 ms
豆包搜索结果（原始查询:Adlai Nortye ANL stock October 2026 decline AN4035 news；API SearchType:web） - validate_order 成功 stock_tools HTTP · 8 ms
{
原文全文
展开原文 · 2,578 字
Adlai Nortye Group (ANL) has entered into clinical trial collaboration and supply agreements with Eli Lilly and Company (LLY) and Merck KGaA (MKKGY), Darmstadt, Germany to evaluate its investigational cancer therapy AN4035 in combination with cetuximab (ERBITUX).
The collaboration will support Adlai Nortye's ongoing global Phase I trial of AN4035, which is being studied both as a standalone treatment and in combination with cetuximab in patients with CEACAM5-enriched, RAS-driven solid tumors. These cancers commonly include colorectal, pancreatic and lung cancers, where RAS mutations are frequently observed.
AN4035 is a first-in-class antibody-drug conjugate (ADC) designed to target CEACAM5 and deliver a pan-RAS(ON) inhibitor directly to tumor cells. The approach is intended to selectively target cancer cells while potentially reducing some of the challenges associated with systemic RAS inhibition.
Under the agreements, Lilly will provide cetuximab at no cost for trial sites in the United States, while Merck KGaA, Darmstadt, Germany will supply the drug for study sites in Australia and China. Adlai Nortye will remain the sponsor of the trial.
The Phase I study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035. According to the company, the monotherapy and combination-treatment arms will begin on a staggered timeline.
The collaboration is based on the scientific rationale of simultaneously targeting EGFR and RAS signaling pathways, a strategy that researchers believe could be beneficial in RAS-driven cancers. Adlai Nortye said AN4035's targeted delivery approach may help broaden the therapeutic potential of combining a pan-RAS inhibitor with cetuximab.
The agreement expands the clinical development program for AN4035 as Adlai Nortye continues to evaluate the investigational therapy in patients with difficult-to-treat solid tumors.
ANL has traded between $0.88 and $17.25 over the past year. The stock closed Wednesday's trading at $10.88, down 7.44%. In pre-market trading the stock is at $11.25, up 3.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
The collaboration will support Adlai Nortye's ongoing global Phase I trial of AN4035, which is being studied both as a standalone treatment and in combination with cetuximab in patients with CEACAM5-enriched, RAS-driven solid tumors. These cancers commonly include colorectal, pancreatic and lung cancers, where RAS mutations are frequently observed.
AN4035 is a first-in-class antibody-drug conjugate (ADC) designed to target CEACAM5 and deliver a pan-RAS(ON) inhibitor directly to tumor cells. The approach is intended to selectively target cancer cells while potentially reducing some of the challenges associated with systemic RAS inhibition.
Under the agreements, Lilly will provide cetuximab at no cost for trial sites in the United States, while Merck KGaA, Darmstadt, Germany will supply the drug for study sites in Australia and China. Adlai Nortye will remain the sponsor of the trial.
The Phase I study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of AN4035. According to the company, the monotherapy and combination-treatment arms will begin on a staggered timeline.
The collaboration is based on the scientific rationale of simultaneously targeting EGFR and RAS signaling pathways, a strategy that researchers believe could be beneficial in RAS-driven cancers. Adlai Nortye said AN4035's targeted delivery approach may help broaden the therapeutic potential of combining a pan-RAS inhibitor with cetuximab.
The agreement expands the clinical development program for AN4035 as Adlai Nortye continues to evaluate the investigational therapy in patients with difficult-to-treat solid tumors.
ANL has traded between $0.88 and $17.25 over the past year. The stock closed Wednesday's trading at $10.88, down 7.44%. In pre-market trading the stock is at $11.25, up 3.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6a8018e61c· 2026-10-15 21:17 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前